CLS receives SEK 22.4 million through the exercise of warrants of series TO 7 B and decides on a directed issue
The exercise period for Clinical Laserthermia Systems AB ("CLS" or the "Company") warrants of series TO 7 B took place during the period from and including November 11, 2024 to and including November 22, 2024. A total of 4 512 532 warrants were exercised for the subscription of 4 512 532 new shares, corresponding to approximately SEK 16,6 million and a subscription rate of approximately 74 percent. In order to ensure that the proceeds amounted to 100%, the Company has also decided on a directed issue to a consortium of new and existing investors of approximately SEK 5,8 million (the "Directed